Pixantrone beyond monotherapy: a review

Cristina Barrenetxea Lekue; Silvina Grasso Cicala; Sirpa Leppä; Thomas Stauffer Larsen; Susana Herráez Rodríguez; Clara Alonso Caballero; Judit M. Jørgensen; Helle Toldbod; Irene Leal Martínez; Francesco D’Amore

doi:10.1007/s00277-019-03749-0

Pixantrone beyond monotherapy: a review

Cristina Barrenetxea Lekue^*, Silvina Grasso Cicala, Sirpa Leppä, Thomas Stauffer Larsen, Susana Herráez Rodríguez, Clara Alonso Caballero, Judit M. Jørgensen, Helle Toldbod, Irene Leal Martínez, Francesco D’Amore

^*Corresponding author for this work

Department of Clinical Medicine - Department of Haematology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

14 Citations (Scopus)

35 Downloads (Pure)

Abstract

Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxorubicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplatin), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent NHL.

Original language	English
Journal	Annals of Hematology
Volume	98
Issue	9
Pages (from-to)	2025-2033
Number of pages	9
ISSN	0939-5555
DOIs	https://doi.org/10.1007/s00277-019-03749-0
Publication status	Published - 1 Jan 2019

Keywords

Antineoplastic efficacy
Cardiotoxicity
Non-Hodgkin’s lymphoma
Pixantrone

Access to Document

10.1007/s00277-019-03749-0

BarrenetxeaLekue2019_Article_PixantroneBeyondMonotherapyAReFinal published version, 343 KBLicence: CC BY

Cite this

@article{15065b81970d446885e99fa8e522ad79,

title = "Pixantrone beyond monotherapy: a review",

abstract = "Outcomes for patients with non-Hodgkin{\textquoteright}s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxorubicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplatin), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent NHL.",

keywords = "Antineoplastic efficacy, Cardiotoxicity, Non-Hodgkin{\textquoteright}s lymphoma, Pixantrone",

author = "{Barrenetxea Lekue}, Cristina and {Grasso Cicala}, Silvina and Sirpa Lepp{\"a} and {Stauffer Larsen}, Thomas and {Herr{\'a}ez Rodr{\'i}guez}, Susana and {Alonso Caballero}, Clara and J{\o}rgensen, {Judit M.} and Helle Toldbod and {Leal Mart{\'i}nez}, Irene and Francesco D{\textquoteright}Amore",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/s00277-019-03749-0",

language = "English",

volume = "98",

pages = "2025--2033",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

TY - JOUR

T1 - Pixantrone beyond monotherapy

T2 - a review

AU - Barrenetxea Lekue, Cristina

AU - Grasso Cicala, Silvina

AU - Leppä, Sirpa

AU - Stauffer Larsen, Thomas

AU - Herráez Rodríguez, Susana

AU - Alonso Caballero, Clara

AU - Jørgensen, Judit M.

AU - Toldbod, Helle

AU - Leal Martínez, Irene

AU - D’Amore, Francesco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxorubicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplatin), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent NHL.

AB - Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines such as doxorubicin limits options at later stages of treatment because of anthracycline-related cumulative cardiotoxicity. The aza-anthracenedione pixantrone was developed to reduce the likelihood of cardiotoxicity without compromising efficacy and is currently conditionally approved for use as monotherapy in patients with multiply-relapsed or refractory aggressive B cell NHL. The use of pixantrone in combination therapy, often to replace doxorubicin or mitoxantrone, has or is currently being investigated in numerous studies in patients with aggressive or indolent NHL and is the focus of this review. These include the R-CPOP regimen (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) for aggressive NHL in the first-line setting, including a study in elderly patients with limited cardiac function, and for patients with relapsed NHL with prior anthracycline exposure; the PSHAP regimen (pixantrone, cytarabine, prednisone, cisplatin), also in the latter setting; the PREBen/PEBen regimen (pixantrone, bendamustine and etoposide with or without rituximab) as salvage therapy; and pixantrone in combination with fludarabine, dexamethasone, and rituximab (FPD-R) for relapsed indolent NHL.

KW - Antineoplastic efficacy

KW - Cardiotoxicity

KW - Non-Hodgkin’s lymphoma

KW - Pixantrone

UR - http://www.scopus.com/inward/record.url?scp=85068980477&partnerID=8YFLogxK

U2 - 10.1007/s00277-019-03749-0

DO - 10.1007/s00277-019-03749-0

M3 - Review

C2 - 31312929

AN - SCOPUS:85068980477

SN - 0939-5555

VL - 98

SP - 2025

EP - 2033

JO - Annals of Hematology

JF - Annals of Hematology

IS - 9

ER -

Pixantrone beyond monotherapy: a review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this